Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 143Recruiting 111Not yet recruiting 59Completed 45Active not recruiting 20Terminated 7Withdrawn 3Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Melanoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × sintilimab × Clear all
NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Neoplasms

NCT04625543 2022-04-26

Neoadjuvant Immunotherapy to ESCC

Qilu Hospital of Shandong University

Phase 2 Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04398927 2021-02-04

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Sun Yat-sen University

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡